Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (617)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00045396 | A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS) | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00004918 | Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI) |
| 1 |
| Jan 7, 2013 |
| clinicaltrials |
| NCT00915252 | Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)(AML-AZA) | completed | Phase 2 | 214 | University Hospital MuensterOTHER | 1 | Dec 17, 2012 | clinicaltrials |
| NCT00790855 | Bendamustine in Acute Leukemia and MDS | terminated | Phase 1 / Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 4, 2012 | clinicaltrials |
| NCT01037556 | PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia | unknown | Phase 1 / Phase 2 | 50 | Proacta, IncorporatedINDUSTRY | 1 | Aug 31, 2012 | clinicaltrials |
| NCT00219726 | Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation | completed | Phase 2 | 30 | Poitiers University HospitalOTHER | 1 | Aug 29, 2012 | clinicaltrials |
| NCT00030186 | Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation | completed | Phase 2 | 37 | CephalonINDUSTRY | 0 | Aug 23, 2012 | clinicaltrials |
| NCT00762632 | Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 40 | Technical University of MunichOTHER | 1 | Aug 8, 2012 | clinicaltrials |
| NCT00088218 | Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS). | completed | Phase 2 | 95 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00267085 | Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00382590 | Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00418951 | Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections | completed | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00480987 | Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) | terminated | Phase 1 / Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT01031498 | Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting | completed | Phase 2 | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00038831 | Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS | completed | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00451997 | Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes | completed | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00569010 | Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00780598 | Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML(OPAL) | completed | Phase 2 | 76 | Chroma TherapeuticsINDUSTRY | 3 | Jun 28, 2012 | clinicaltrials |
| NCT01627132 | Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial | unknown | Phase 2 | 50 | Shimousa Hematology Study GroupOTHER | 1 | Jun 25, 2012 | clinicaltrials |
| NCT00326170 | Phase II 5-Azacytidine Plus VPA Plus ATRA | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2012 | clinicaltrials |
| NCT00071006 | AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 12 | PfizerINDUSTRY | 1 | Jun 8, 2012 | clinicaltrials |
| NCT00111345 | Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents | unknown | Phase 2 / Phase 3 | 550 | University Hospital MuensterOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT00570999 | Palifermin After Haploidentical PBSCT(KGF Haplo Allo) | withdrawn | Phase 2 | 0 | European Society for Blood and Marrow TransplantationNETWORK | 1 | May 10, 2012 | clinicaltrials |
| NCT00719836 | A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies | completed | Phase 1 / Phase 2 | 76 | S*BIOINDUSTRY | 1 | Apr 20, 2012 | clinicaltrials |
| NCT01170598 | Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy | completed | Phase 2 | 35 | Toronto Rehabilitation InstituteOTHER | 1 | Apr 20, 2012 | clinicaltrials |
| NCT00270881 | Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 33 | Keio UniversityOTHER | 1 | Apr 6, 2012 | clinicaltrials |
| NCT00887042 | Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML | unknown | Phase 1 / Phase 2 | 35 | The Korean Society of Pediatric Hematology OncologyNETWORK | 1 | Mar 26, 2012 | clinicaltrials |
| NCT01556477 | The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q). | unknown | Phase 2 | 72 | Nordic MDS GroupNETWORK | 1 | Mar 16, 2012 | clinicaltrials |
| NCT00101660 | Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib | completed | Phase 2 | 387 | Bristol-Myers SquibbINDUSTRY | 22 | Mar 2, 2012 | clinicaltrials |
| NCT00493181 | Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT01534702 | Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML(CIARA) | unknown | Phase 1 / Phase 2 | 60 | Hannover Medical SchoolOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT01180426 | Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 2 | 30 | Chroma TherapeuticsINDUSTRY | 1 | Feb 15, 2012 | clinicaltrials |
| NCT00764231 | A Study of a Home-based Exercise Intervention for Patients With Acute Myeloid Leukaemia (AML) | completed | Phase 2 | 40 | Toronto Rehabilitation InstituteOTHER | 1 | Feb 8, 2012 | clinicaltrials |
| NCT00144677 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00144703 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation | completed | Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00795548 | Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation | completed | Phase 2 | 30 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Jan 23, 2012 | clinicaltrials |
| NCT00088231 | PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP | completed | Phase 1 / Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT01513109 | Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia(ASCI) | unknown | Phase 1 / Phase 2 | 20 | Jules Bordet InstituteOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT01513603 | Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia | unknown | Phase 2 | 50 | New York Medical CollegeOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT00895297 | Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia(Dasatinib) | terminated | Phase 2 | 50 | European Society for Blood and Marrow TransplantationNETWORK | 4 | Dec 7, 2011 | clinicaltrials |
| NCT01003054 | Autologous Transplantation for Chronic Myelogenous Leukemia | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 2, 2011 | clinicaltrials |
| NCT00763763 | Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive(AFR07) | completed | Phase 2 | 55 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 5, 2011 | clinicaltrials |
| NCT01011998 | A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) | withdrawn | Phase 2 | 0 | New Mexico Cancer Research AllianceOTHER | 1 | Sep 27, 2011 | clinicaltrials |
| NCT01423175 | ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS(ClAraC-SCT) | unknown | Phase 2 | 60 | Hannover Medical SchoolOTHER | 1 | Aug 29, 2011 | clinicaltrials |
| NCT00760084 | Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 10 | Eisai Inc.INDUSTRY | 1 | Aug 8, 2011 | clinicaltrials |
| NCT00339196 | 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS | completed | Phase 2 | 25 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 9, 2011 | clinicaltrials |
| NCT00162513 | Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | — | Hadassah Medical OrganizationOTHER | 1 | Apr 28, 2011 | clinicaltrials |
| NCT00101647 | Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia | completed | Phase 2 | 197 | Bristol-Myers SquibbINDUSTRY | 23 | Apr 15, 2011 | clinicaltrials |
| NCT00101595 | Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | completed | Phase 2 | 96 | Bristol-Myers SquibbINDUSTRY | 20 | Apr 14, 2011 | clinicaltrials |
| NCT00337454 | Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan | completed | Phase 1 / Phase 2 | 48 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 14, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Jan 9, 2013source: clinicaltrials